Skip to content

Known Risks

Why This Page Exists

Sophisticated audiences respect founders who name their risks. Pretending they don’t exist signals naivete. Addressing them directly builds trust.

Regulatory

CMS Could Standardize File Formats

If CMS mandates a single file format for hospital pricing, it would reduce the parsing complexity that is one dimension of ClearPrice’s moat.

Mitigation: This would actually be good for the market and accelerate ClearPrice’s coverage expansion. The moat is increasingly in fused intelligence (rates + Medicare + plans + quality) and data quality — not solely in parsing. And government standardization takes years.

Regulatory

CMS Could Build a Government Consumer Tool

CMS has the data. They could theoretically build a consumer-facing price comparison tool.

Mitigation: Government-built consumer tools have a consistent track record of underperformance relative to market alternatives. ClearPrice would continue serving B2B segments regardless.

Competitive

Turquoise Health Could Move Downstream

Turquoise has $60M+ in funding and could decide to build consumer or advisor products.

Mitigation: Enterprise data companies rarely execute well on consumer product design — different customer, different sales motion, different product instinct. ClearPrice’s consumer-first architecture represents fundamentally different product decisions.

Competitive

Major Payer Could Build Internally

UnitedHealth Group or Elevance could build an internal transparency tool with their own data.

Mitigation: Payers have conflicting incentives around full transparency — genuine cross-payer comparison can highlight unfavorable rate differentials. An independent third party has credibility that a payer-owned tool does not.

Execution

Solo Founder Dependency

The entire platform — pipeline, products, operations — was built by one person. Bus factor = 1.

Mitigation: Platform designed for operational independence: automated weekly pipeline, CI/CD deployment, test suites, structured documentation. Team-building is the explicit next phase, not an afterthought.

Execution

Pre-Revenue

No revenue yet. Products are live and operational, but nobody has written a check.

Mitigation: Product is built, data is operational, go-to-market plan is defined with specific segments and targets. Revenue timeline: first broker pilot conversations Q2 2026. The product risk is behind us — the market risk is ahead.